Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

Ferring has announced the opening of the first clinical trial sites for 2 studies within the ABLE clinical trial program as well as the launch of the phase 1/2 LUNAR trial. “The combination of ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

Lenvatinib/pembrolizumab and nivolumab/cabozantinib show improved survival and response rates in advanced renal cell carcinoma. Machine learning and surgical algorithms are advancing personalized ...

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy. This condition requires alternative therapeutic strategies or radical ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...